<DOC>
	<DOCNO>NCT01953055</DOCNO>
	<brief_summary>Current treatment option high risk localize prostate cancer include radical prostatectomy +/- postoperative radiotherapy , radical radiotherapy androgen deprivation therapy . Evidence emerge prostate cancer low α/β ratio range 1-3 Gy . Even high risk tumor , prostate cancer hypothesize great sensitivity large fraction size high dose per fraction radiotherapy theoretically allow biological dose escalation few visit additional toxicity . Therefore , hope determine toxicity , quality life , biochemical pathological control SBRT high risk prostate cancer incorporate ENI .</brief_summary>
	<brief_title>SABR Including Regional Lymph Node Irradiation Patients With High Risk Prostate Cancer ( SATURN )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>informed consent obtain men &gt; 18 year age histologically confirm prostate adenocarcinoma ( centrally review ) high risk prostate cancer , define least one clinical stage T3 Gleason 810 , PSA &gt; 20ng/mL prior pelvic radiotherapy anticoagulation medication ( unsafe discontinue gold seed insertion ) diagnosis bleed diathesis large prostate ( &gt; 90cm3 ) imaging time gold seed insertion evidence castrate resistance ( define PSA &lt; 3ng/mL testosterone &lt; 0.7nmol/L definitive regional distant metastatic disease stag investigation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stereotactic ablative radiotherapy</keyword>
	<keyword>androgen deprivation therapy</keyword>
</DOC>